Core Laboratories Inc. (NYSE:CLB) Sees Large Decline in Short Interest

Core Laboratories Inc. (NYSE:CLB) saw a significant decline in short interest in July. As of July 15th, there was short interest totaling 4,023,689 shares, a decline of 32.6% from the June 30th total of 5,971,336 shares. Based on an average trading volume of 1,615,519 shares, the short-interest ratio is presently 2.5 days. Approximately 8.8% of the shares of the stock are short sold.

Key Core Laboratories News

Here are the key news stories impacting Core Laboratories this week:

• Positive Sentiment: Core Laboratories reported adjusted earnings of $0.11 per share, exceeding the $0.08 analyst consensus. Adjusted operating income rose 42% sequentially, while revenue increased 2% from the first quarter. Core Laboratories Q2 Earnings Surpass Estimates
• Positive Sentiment: The company repurchased 214,712 shares for approximately $2.7 million and generated $3.1 million in free cash flow, signaling continued capital-return activity despite challenging market conditions. Core Lab Reports Second Quarter 2026 Results
• Neutral Sentiment: Core Laboratories declared a quarterly dividend of $0.01 per share, payable August 31 to shareholders of record August 10. The annualized yield is approximately 0.4%, making the dividend a modest support rather than a major stock catalyst.
• Neutral Sentiment: Management’s third-quarter revenue outlook of $128.5 million to $135.5 million broadly brackets the $132.5 million consensus estimate, while the earnings call provided additional commentary on the company’s outlook and operating trends. Core Laboratories Q2 2026 Earnings Call Transcript
• Negative Sentiment: Second-quarter revenue of $124.6 million missed the $126.3 million consensus estimate and declined 4.3% year over year. Adjusted EPS also fell from $0.19 a year earlier, indicating that the earnings beat was driven against lowered expectations rather than underlying year-over-year growth. Core Laboratories Misses Q2 Sales Expectations
• Negative Sentiment: Third-quarter EPS guidance of $0.12 to $0.20 has a midpoint of $0.16, below the $0.17 analyst consensus, reinforcing concerns about near-term profitability.

Core Laboratories Stock Up 5.0%

Shares of NYSE CLB opened at $10.37 on Friday. The stock has a market capitalization of $477.87 million, a P/E ratio of 18.51, a PEG ratio of 2.38 and a beta of 1.00. Core Laboratories has a one year low of $9.72 and a one year high of $20.36. The firm’s 50 day simple moving average is $12.08 and its two-hundred day simple moving average is $15.26. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.05 and a quick ratio of 1.50.

Core Laboratories (NYSE:CLB) last announced its quarterly earnings data on Wednesday, July 29th. The oil and gas company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.03. Core Laboratories had a net margin of 5.10% and a return on equity of 10.06%. The firm had revenue of $124.61 million during the quarter, compared to analyst estimates of $126.26 million. During the same period in the previous year, the business posted $0.19 EPS. The business’s quarterly revenue was down 4.3% on a year-over-year basis. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS. As a group, analysts expect that Core Laboratories will post 0.53 EPS for the current fiscal year.

Core Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Monday, August 10th will be paid a $0.01 dividend. The ex-dividend date of this dividend is Monday, August 10th. This represents a $0.04 annualized dividend and a yield of 0.4%. Core Laboratories’s payout ratio is currently 6.15%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on CLB. Weiss Ratings downgraded Core Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, June 24th. Wall Street Zen cut Core Laboratories from a “hold” rating to a “sell” rating in a report on Saturday, July 4th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Reduce”.

Institutional Trading of Core Laboratories

Institutional investors have recently added to or reduced their stakes in the business. Disciplined Growth Investors Inc. MN grew its stake in shares of Core Laboratories by 9.7% during the third quarter. Disciplined Growth Investors Inc. MN now owns 5,969,860 shares of the oil and gas company’s stock valued at $73,787,000 after buying an additional 528,976 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Core Laboratories by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 3,079,882 shares of the oil and gas company’s stock valued at $49,371,000 after acquiring an additional 32,492 shares during the last quarter. State Street Corp lifted its stake in shares of Core Laboratories by 3.3% in the 4th quarter. State Street Corp now owns 2,041,740 shares of the oil and gas company’s stock valued at $32,729,000 after acquiring an additional 64,831 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Core Laboratories by 10.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,352,329 shares of the oil and gas company’s stock valued at $22,705,000 after acquiring an additional 122,718 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Core Laboratories by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 1,114,935 shares of the oil and gas company’s stock valued at $17,876,000 after acquiring an additional 8,497 shares during the period. 97.81% of the stock is currently owned by hedge funds and other institutional investors.

Core Laboratories Company Profile

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company’s portfolio spans two primary service lines: reservoir description and production enhancement.